In this interactive session, Life Sciences CEOs will explain what their concerns are while evaluating opportunities outside their organizations and maximizing the opportunities inside their organizations. Topics will include:
- How does a CEO incorporate shareholder valuation into the due diligence process?
- How do you measure acceptable risk?
- What due diligence factors do you use in selecting a partner for a collaboration agreement?
Panelists include: George Daniloff, CEO, Carbylan BioSurgery; Dinesh V. Patel, Ph.D., President and CEO, Arête Therapeutics; Tom Moran, Of Counsel, Foley; Jay Sheppard, President and Chief Executive Officer, Relypsa, Inc.; and James A. D. Smith, President and Chief Executive Officer, Genelabs.
Related Insights
July 25, 2025
Foley Viewpoints
Thorny Laws That ICHRA Vendors Should Consider, Part Three: FinTech Edition
We continue our series on the legal and regulatory challenges facing individual coverage health reimbursement arrangements (ICHRAs); this…
July 24, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…
July 23, 2025
Foley Viewpoints
The One Big Beautiful Bill and Workplace Immigration Enforcement
The “One Big Beautiful Bill Act,” signed into law by President Trump on July 4, 2025, will fund government efforts to continue to…